Join Clinical Trials in Mississippi for Depression

All Categories Most Often Searched » Depression » Mississippi

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder

Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Condition: Major Depressive Disorder
Interventions: Drug: PNB01 fixed dose combination of pipamperone and citalopram; Drug: Citalopram; Drug: Pipamperone
Sponsors: PharmaNeuroBoost N.V.; PharmaNeuroBoost N.V.
Recruiting - verified March 2012
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

Condition: Bipolar
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Condition: Major Depressive Disorder (MDD)
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Conditions: Bipolar; Depression
Intervention: Drug: lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified February 2012